vimarsana.com

Latest Breaking News On - சீன இதழ் - Page 14 : vimarsana.com

Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Acasti Pharma (NASDAQ:ACST) - The Daily Biotech Pulse: Fluidigm s Saliva-Based COVID Test Approved In Europe, China Backs Amarin s Vascepa

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Acasti Pharma (NASDAQ:ACST) - The Daily Biotech Pulse: Fluidigm s Saliva-Based COVID Test Approved In Europe, China Backs Amarin s Vascepa
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Lies Abound at Beijing s Pandemic Press Conference

Lies Abound at Beijing’s Pandemic Press Conference Commentary China’s State Council and National Health Commission held a press conference on Jan. 13 to share information on the country’s recent pandemic control measures. It turned out to be another round of lies and deception from so-called medical experts. Journalists from Chinese and Hong Kong-based media participated in the deception by asking the public health officials canned questions. Let’s take a look at some of the biggest fabrications during the press conference. ‘There Won’t Be Large-Scale Resurgence’ According to a transcript published on the National Health Commission website, a reporter from state-run media Xinhua asked: “There are currently one high-risk and 73 medium-risk areas across the country … Will there be a resurgence?”

Trial PROSPERs China s fight against advancing prostate cancer

Trial PROSPERs China’s fight against advancing prostate cancer New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer, Peter Doyle reports It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most populous country for patients with advanced prostate cancer, China’s medicine regulator, the National Medical Products Administration (NMPA), approved the oral androgen-receptor inhibitor enzalutamide for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.

Global Times: Китайски експерти настояват да се спре ваксината Pfizer!

Global Times: Китайски експерти настояват да се спре ваксината Pfizer!
blitz.bg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blitz.bg Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.